Intra-Cellular Therapies Inc (ITCI)
72.36
+0.32
(+0.44%)
USD |
NASDAQ |
Apr 19, 16:00
72.36
0.00 (0.00%)
After-Hours: 16:59
Intra-Cellular Therapies Enterprise Value: 6.476B for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 6.476B |
| April 17, 2024 | 6.926B |
| April 16, 2024 | 7.231B |
| April 15, 2024 | 5.771B |
| April 12, 2024 | 5.880B |
| April 11, 2024 | 6.082B |
| April 10, 2024 | 6.015B |
| April 09, 2024 | 6.145B |
| April 08, 2024 | 6.056B |
| April 05, 2024 | 6.128B |
| April 04, 2024 | 6.008B |
| April 03, 2024 | 6.019B |
| April 02, 2024 | 5.956B |
| April 01, 2024 | 6.111B |
| March 28, 2024 | 6.201B |
| March 27, 2024 | 6.251B |
| March 26, 2024 | 6.020B |
| March 25, 2024 | 6.082B |
| March 22, 2024 | 6.184B |
| March 21, 2024 | 6.122B |
| March 20, 2024 | 6.008B |
| March 19, 2024 | 5.838B |
| March 18, 2024 | 5.830B |
| March 15, 2024 | 5.773B |
| March 14, 2024 | 5.753B |
| Date | Value |
|---|---|
| March 13, 2024 | 5.815B |
| March 12, 2024 | 5.734B |
| March 11, 2024 | 5.836B |
| March 08, 2024 | 6.035B |
| March 07, 2024 | 5.961B |
| March 06, 2024 | 5.894B |
| March 05, 2024 | 5.951B |
| March 04, 2024 | 6.010B |
| March 01, 2024 | 6.423B |
| February 29, 2024 | 6.232B |
| February 28, 2024 | 6.388B |
| February 27, 2024 | 6.559B |
| February 26, 2024 | 6.430B |
| February 23, 2024 | 6.294B |
| February 22, 2024 | 6.465B |
| February 21, 2024 | 6.596B |
| February 20, 2024 | 6.637B |
| February 16, 2024 | 6.793B |
| February 15, 2024 | 6.720B |
| February 14, 2024 | 6.440B |
| February 13, 2024 | 6.287B |
| February 12, 2024 | 6.512B |
| February 09, 2024 | 6.516B |
| February 08, 2024 | 6.403B |
| February 07, 2024 | 6.111B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
128.50M
Minimum
Sep 27 2019
7.231B
Maximum
Apr 16 2024
2.977B
Average
2.802B
Median
Nov 15 2021
Enterprise Value Benchmarks
| Insmed Inc | 4.057B |
| Fate Therapeutics Inc | 184.98M |
| ADMA Biologics Inc | 1.494B |
| Rhythm Pharmaceuticals Inc | 2.016B |
| Amylyx Pharmaceuticals Inc | -237.83M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.58M |
| Revenue (Quarterly) | 131.51M |
| Total Expenses (Quarterly) | 165.60M |
| EPS Diluted (Quarterly) | -0.30 |
| Gross Profit Margin (Quarterly) | 91.86% |
| Profit Margin (Quarterly) | -21.73% |
| Earnings Yield | -2.02% |
| Normalized Earnings Yield | -2.018 |